en
svPress releases
Regulatory press release 2021-02-25
Xspray Pharma publishes Interim report Q4, January – December 2020
Regulatory press release 2021-02-17
Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma
Regulatory press release 2021-01-29
Number of shares and votes in Xspray Pharma
Regulatory press release 2021-01-26
Warrant holders exercise all warrants within the framework of the incentive program
Regulatory press release 2021-01-22
Xspray Pharmas study with modified formulation of HyNap-Dasa has now started
Regulatory press release 2021-01-14
Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2)
Regulatory press release 2020-12-29
Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia
Regulatory press release 2020-12-11
Xspray Pharma has decided to await the result of two ongoing clinical studies before submitting its ANDA application
Regulatory press release 2020-11-20
Xspray Pharma publishes Interim Report Q3, January – September 2020
Regulatory press release 2020-10-30